<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02948244</url>
  </required_header>
  <id_info>
    <org_study_id>36298</org_study_id>
    <nct_id>NCT02948244</nct_id>
  </id_info>
  <brief_title>Effect of Creatine Monohydrate on Functional Muscle Strength in Children With FSHD</brief_title>
  <official_title>Effect of Creatine Monohydrate on Functional Muscle Strength and Muscle Mass in Children With FSHD: a Multi-centre, Randomised, Double-blind Placebo-controlled Crossover Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Murdoch Childrens Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Murdoch Childrens Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-centre, randomised, double-blind, placebo-controlled crossover trial will compare
      changes in strength-related motor function following treatment with creatine monohydrate to
      treatment with placebo, as measured by the Motor Function Measure, from baseline to 12 weeks.
      Eligible subjects will undergo baseline assessments then will be randomised to either
      creatine monohydrate therapy or placebo for three months, followed by a six week wash-out
      period, then crossover to a further three months of therapy with either placebo or creatine.
      Subjects will undergo clinical assessments and study safety assessments at the beginning and
      end of each treatment period. The study will begin recruitment in early 2017.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 31, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Motor Function Measure for Neuromuscular disease</measure>
    <time_frame>3 months</time_frame>
    <description>Composite functional outcome measure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle Magnetic Resonance Imaging</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Ultrasound Scan</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance of the Upper Limb Measure</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACTIVILIM</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PedsQL Neuromuscular</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FSH-COM</measure>
    <time_frame>3 months</time_frame>
    <description>FSHD specific composite measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FSH-Health Index (Pediatric Version)</measure>
    <time_frame>3 months</time_frame>
    <description>Patient reported outcome measure specific for patients with FSHD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six Minute Walk Test</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FSHD Severity Score</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative muscle strength testing</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GPX3 Level</measure>
    <time_frame>3 months</time_frame>
    <description>Possible biomarker of disease severity in FSHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Step Counter</measure>
    <time_frame>3 months</time_frame>
    <description>Physical activity measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory safety monitoring</measure>
    <time_frame>3 months</time_frame>
    <description>bloods and urine safety testing (urea and electrolytes, urine plasma creatine:creatinine ratios)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Facio-Scapulo-Humeral Dystrophy</condition>
  <condition>FSHD2</condition>
  <condition>FSHD1</condition>
  <arm_group>
    <arm_group_label>Group A - Active/Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive 3 months of creatine monohydrate followed by a 6 week washout period followed by 3 months of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B - Placebo/Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive 3 months of placebo followed by a 6 week washout period followed by 3 months of creatine monohydrate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Creatine Monohydrate</intervention_name>
    <description>Synthetically produced dietary supplement Creatine Monohydrate will be used in powder form reconstituted to a drink. The dosage will be 100mg/kg/day up to a maximum of 10 grams daily.</description>
    <arm_group_label>Group A - Active/Placebo</arm_group_label>
    <arm_group_label>Group B - Placebo/Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Group A - Active/Placebo</arm_group_label>
    <arm_group_label>Group B - Placebo/Active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is between the ages of 5 and 18 years inclusive at the time of randomisation;

          -  Has a confirmed genetic diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD)
             types 1 or 2;

          -  Has a legally acceptable representative capable of understanding the informed consent
             document and providing consent on the participant's behalf.

        Exclusion Criteria:

          -  Has clinically significant elevation in plasma creatinine level or unexplained
             hypertension at screening;

          -  Has a prior diagnosis of chronic renal failure;

          -  Has a known hypersensitivity to creatine monohydrate of maltodextrin placebo;

          -  Patients already taking any medications to increase muscle bulk or strength or
             concomitant use of regular sodium valproate, corticosteroids of alpha agonists such as
             salbutamol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian R Woodcock, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Murdoch Children Research Institute/Royal Children Hospital, Melbourne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Monique M Ryan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Murdoch Children Research Institute/Royal Children Hospital, Melbourne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ian R Woodcock, MBBS</last_name>
    <phone>+61 3 9345 5661</phone>
    <email>ian.woodcock@rch.org.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monique M Ryan</last_name>
    <phone>+61 3 9345 5661</phone>
    <email>neurology.department@rch.org.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Royal Children's Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian R Woodcock, MBBS, MSc</last_name>
      <phone>+61 (0) 3 9345 5661</phone>
      <email>ian.woodcock@rch.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Daniella Villano, BN</last_name>
      <phone>+61 (0) 3 9345 5661</phone>
      <email>daniella.villano@rch.org.au</email>
    </contact_backup>
    <investigator>
      <last_name>Ian R Woodcock, MBBS, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katy de Valle, BSc Physio</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2016</study_first_submitted>
  <study_first_submitted_qc>October 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2016</study_first_posted>
  <last_update_submitted>November 13, 2017</last_update_submitted>
  <last_update_submitted_qc>November 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fshd</keyword>
  <keyword>creatine monohydrate</keyword>
  <keyword>children</keyword>
  <keyword>pediatrics</keyword>
  <keyword>Facio-Scapulo-Humeral Dystrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophy, Facioscapulohumeral</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

